Clinical translation of hidradenitis suppurativa genetic studies requires global collaboration
Br J Dermatol
.
2022 Jan;186(1):183-185.
doi: 10.1111/bjd.20749.
Epub 2021 Nov 8.
Authors
A J Jabbour
1
,
K R van Straalen
2
3
,
A Colvin
4
,
E P Prens
2
3
,
L Petukhova
5
6
Affiliations
1
The University of Queensland-Ochsner Clinical School, New Orleans, LA, USA.
2
Erasmus University Medical Center Rotterdam, Laboratory for Experimental Immunodermatology, Rotterdam, the Netherlands.
3
Department of Dermatology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
4
Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
5
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
6
Department of Dermatology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
PMID:
34498254
PMCID:
PMC8738108
DOI:
10.1111/bjd.20749
No abstract available
Publication types
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
MeSH terms
Adalimumab
Hidradenitis Suppurativa* / genetics
Humans
Severity of Illness Index
Translations
Substances
Adalimumab
Grants and funding
P30 AR069632/AR/NIAMS NIH HHS/United States
KL2 TR001874/TR/NCATS NIH HHS/United States
K01 AR075111/AR/NIAMS NIH HHS/United States
L60 AR077958/AR/NIAMS NIH HHS/United States
UL1 TR001873/TR/NCATS NIH HHS/United States